These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37028833)

  • 1. Scleroderma Skin: How Is Treatment Best Guided by Data and Implemented in Clinical Practice?
    Vonk MC; Assassi S; Hoffmann-Vold AM
    Rheum Dis Clin North Am; 2023 May; 49(2):249-262. PubMed ID: 37028833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging biomarkers in systemic sclerosis.
    Manetti M
    Curr Opin Rheumatol; 2016 Nov; 28(6):606-12. PubMed ID: 27380110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Plasma Cell Gene Signature Predicts Improvement in Systemic Sclerosis Skin Scores Following Treatment With Inebilizumab (MEDI-551) and Correlates With Disease Activity in Systemic Lupus Erythematosus and Chronic Obstructive Pulmonary Disease.
    Streicher K; Sridhar S; Kuziora M; Morehouse CA; Higgs BW; Sebastian Y; Groves CJ; Pilataxi F; Brohawn PZ; Herbst R; Ranade K
    Arthritis Rheumatol; 2018 Dec; 70(12):2087-2095. PubMed ID: 29956883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Type-Specific Biomarkers of Systemic Sclerosis Disease Severity Capture Cell-Intrinsic and Cell-Extrinsic Circuits.
    Berkowitz JS; Tabib T; Xiao H; Sadej GM; Khanna D; Fuschiotti P; Lafyatis RA; Das J
    Arthritis Rheumatol; 2023 Oct; 75(10):1819-1830. PubMed ID: 37096444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do We Have Good Activity Indices in Systemic Sclerosis?
    Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R
    Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.
    Martyanov V; Kim GJ; Hayes W; Du S; Ganguly BJ; Sy O; Lee SK; Bogatkevich GS; Schieven GL; Schiopu E; Marangoni RG; Goldin J; Whitfield ML; Varga J
    PLoS One; 2017; 12(11):e0187580. PubMed ID: 29121645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers in systemic sclerosis.
    Skaug B; Assassi S
    Curr Opin Rheumatol; 2019 Nov; 31(6):595-602. PubMed ID: 31436584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data.
    Martyanov V; Whitfield ML
    Curr Opin Rheumatol; 2016 Jan; 28(1):83-8. PubMed ID: 26555452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of skin involvement in systemic sclerosis.
    Kumánovics G; Péntek M; Bae S; Opris D; Khanna D; Furst DE; Czirják L
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v53-v66. PubMed ID: 28992173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time.
    Skaug B; Lyons MA; Swindell WR; Salazar GA; Wu M; Tran TM; Charles J; Vershel CP; Mayes MD; Assassi S
    Ann Rheum Dis; 2022 Apr; 81(4):516-523. PubMed ID: 34937693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasmapheresis therapy in systemic sclerosis].
    Szúcs G; Szamosi S; Aleksza M; Veres K; Soltész P
    Orv Hetil; 2003 Nov; 144(45):2213-7. PubMed ID: 14686006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.
    Low AHL; Ng SA; Berrocal V; Brennan B; Chan G; Ng SC; Khanna D
    Int J Rheum Dis; 2019 Jun; 22(6):1036-1040. PubMed ID: 30838791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta.
    Farina G; Lemaire R; Pancari P; Bayle J; Widom RL; Lafyatis R
    Ann Rheum Dis; 2009 Mar; 68(3):435-41. PubMed ID: 18408251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach.
    Corriveau MP; Boufaied I; Lessard J; Chabaud S; Senécal JL; Grodzicky T; Chartier S; Raymond Y; Moulin VJ
    J Pathol; 2009 Mar; 217(4):534-42. PubMed ID: 19086038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.
    Taroni JN; Greene CS; Martyanov V; Wood TA; Christmann RB; Farber HW; Lafyatis RA; Denton CP; Hinchcliff ME; Pioli PA; Mahoney JM; Whitfield ML
    Genome Med; 2017 Mar; 9(1):27. PubMed ID: 28330499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin score, disease severity, and functional status.
    Gheita TA; Sayed S; Azkalany GS; Abaza N; Hammam N; Eissa AH
    Clin Rheumatol; 2018 Mar; 37(3):757-763. PubMed ID: 29076114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry.
    Khimdas S; Harding S; Bonner A; Zummer B; Baron M; Pope J;
    Arthritis Care Res (Hoboken); 2011 Jan; 63(1):142-9. PubMed ID: 20740608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How much of skin improvement over time in systemic sclerosis is due to normal ageing? A prospective study with shear-wave elastography.
    Santiago T; Santiago M; Coutinho M; Salvador MJ; Da Silva JAP
    Arthritis Res Ther; 2020 Mar; 22(1):50. PubMed ID: 32188488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous hematopoietic stem cell transplantation reverses skin fibrosis but does not change skin vessel density in patients with systemic sclerosis.
    Daikeler T; Kump E; Stern M; Hügle T; Hij A; Haeuserman P; Farge D
    Pathol Biol (Paris); 2015 Sep; 63(4-5):164-8. PubMed ID: 26300240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.
    Showalter K; Merkel PA; Khanna D; Gordon JK
    J Scleroderma Relat Disord; 2020 Oct; 5(3):167-171. PubMed ID: 35382518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.